Category Archives: Health Care

Health Care

بمناسبةشهر التوعية لسرطان القولون والمستقيم، مركز ميموريال سلون كيترنغ لعلاج السرطان يستعرض أحدث التطورات العلاجية

بمناسبة شهر التوعية لسرطان القولون والمستقيم، مركز ميموريال سلون كيترنغ لعلاج السرطان يستعرض أحدث التطورات العلاجية

الابتكار العالمي في علاج سرطان القولون والمستقيم يخدم الحاجة المتزايدة في     الخليج و منطقة الشرق الأوسط

دبي، الرياض، الدوحة – 26 مارس 2026

بمناسبة شهر التوعية لسرطان القولون والمستقيم، يسلّط مركز ميموريال سلون كيترنغ لعلاج السرطان الضوء على التقدم المستجد في علاج سرطان القولون والمستقيم، مع التأكيد على أهمية الفحص والكشف المبكر، وإتاحة الوصول و الاستفادة السريعة من الرعاية المتخصصة في منطقة الشرق الأوسط.

يظل سرطان القولون والمستقيم تحدياً صحياً عالمياً رئيسياً. ففي منطقة الشرق الأوسط وشمال أفريقيا، تتراوح معدلات الإصابة بين نحو 15 و36 حالة لكل 100 ألف نسمة. و يُعد سرطان القولون والمستقيم من بين أكثر أنواع السرطان شيوعاً في دول مجلس التعاون الخليجي. وفي عدد من دول المنطقة، يُعد سبباً رئيسياً للوفاة المرتبطة بالسرطان.  وذلك فيما لا تزال معدلات الإقبال على الفحص أقل مقارنة بالدول الغربية، فيما يؤدى الي تشخيص المرض في مراحل متقدمة.

Continue reading بمناسبةشهر التوعية لسرطان القولون والمستقيم، مركز ميموريال سلون كيترنغ لعلاج السرطان يستعرض أحدث التطورات العلاجية →
Health Care

Advances in Colorectal Cancer Care for the Middle East

During Colorectal Cancer Awareness Month, Memorial Sloan Kettering Cancer Center Showcases New Advances in Care

Global innovation in colorectal cancer care meets growing regional need in the Middle East

DUBAI, RIYADH, DOHA, March 26, 2026. During Colorectal Cancer Awareness Month, Memorial Sloan Kettering Cancer Center (MSK) is spotlighting advances in colorectal cancer care, while emphasizing the importance of screening, early detection, and access to specialized treatment for patients across the Middle East.

Colorectal cancer, which includes cancers of the colon and rectum, remains a major global health challenge. In the Middle East and North Africa region, incidence rates range from approximately 15 to 36 cases per 100,000 people, with colorectal cancer ranking among the most common cancers in Gulf Cooperation Council countries. In several countries across the region, it is a leading cause of cancer related death, and screening uptake remains lower than in Western markets, contributing to later stage diagnoses.

Continue reading Advances in Colorectal Cancer Care for the Middle East →
Featured, Health Care

Orforglipron vs. Semaglutide: A New Era in Diabetes Treatment

Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet

  • For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in ACHIEVE-3
  • In a key secondary endpoint, participants on orforglipron 36 mg lost 19.7 lbs (9.2%) compared to 11.0 lbs (5.3%) with oral semaglutide 14 mg, representing a 73.6% greater relative weight loss
  • Lilly has submitted orforglipron to regulators in over 40 countries, with potential U.S. action for obesity in Q2 2026

INDIANAPOLIS, March 24, 2026 — Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1 without food or water restrictions, compared with oral semaglutide in adults with type 2 diabetes inadequately controlled with metformin. The 52-week trial enrolled 1,698 participants across four treatment arms: orforglipron 12 mg and 36 mg, and oral semaglutide 7 mg and 14 mg. In ACHIEVE-3, orforglipron outperformed oral semaglutide across the primary and all key secondary endpoints, delivering significantly greater improvements in A1C and weight.1,2 The results were published today in The Lancet.

Continue reading Orforglipron vs. Semaglutide: A New Era in Diabetes Treatment →
Health Care

Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss

Dubai, 24 March 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term. The FDA awarded a Commissioner’s National Priority Voucher for Wegovy® HD, accelerating its review and underscoring its potential to address critical patient needs and national health priorities in the US.

The accelerated approval is based on results from the STEP UP trial programme. In the STEP UP trial, semaglutide 7.2 mg injected once weekly demonstrated 20.7%1 mean weight loss in participants with obesity, and approximately one in three people experienced 25% or greater weight loss. In the STEP UP type 2 diabetes (T2D) trial, in participants with obesity and type 2 diabetes, semaglutide 7.2 mg demonstrated a mean weight loss of 14.1%1. In both trials, the well-known safety and tolerability profile of semaglutide was reaffirmed with semaglutide 7.2 mg, which was comparable to previous trials with semaglutide for weight management.

Continue reading Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss →
Health Care

Breathing slowly into a paper bag can help calm the mind quickly, says an expert

A psychologist provides 5 simple and quick calming techniques to help manage panic and stress.

Simple grounding activities like holding ice, touching textures, walking barefoot, or tuning into surrounding sounds can help anchor the mind in the present and ease panic.

17 March, 2026; Ras Al Khaimah, UAE – In times of uncertainty, continuous exposure to distressing news and information can trigger feelings of stress, anxiety and even sudden panic. Mental health experts say that while such reactions are natural, there are simple techniques individuals can use to regain control of their emotions and calm the mind.

Ms Zobia Amin, Clinical Psychologist, RAK Hospital

Continue reading Breathing slowly into a paper bag can help calm the mind quickly, says an expert →